Titre
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Orlando, V.
Auteure/Auteur
Drubay, D.
Auteure/Auteur
Lavaud, P.
Auteure/Auteur
Faivre, L.
Auteure/Auteur
Lesaunier, F.
Auteure/Auteur
Delva, R.
Auteure/Auteur
Gravis, G.
Auteure/Auteur
Rolland, F.
Auteure/Auteur
Priou, F.
Auteure/Auteur
Ferrero, J.M.
Auteure/Auteur
Houede, N.
Auteure/Auteur
Mourey, L.
Auteure/Auteur
Theodore, C.
Auteure/Auteur
Krakowski, I.
Auteure/Auteur
Berdah, J.F.
Auteure/Auteur
Baciuchka, M.
Auteure/Auteur
Laguerre, B.
Auteure/Auteur
Fléchon, A.
Auteure/Auteur
Grosse-Goupil, M.
Auteure/Auteur
Cojean-Zelek, I.
Auteure/Auteur
Oudard, S.
Auteure/Auteur
Labourey, J.L.
Auteure/Auteur
Chinet-Charrot, P.
Auteure/Auteur
Legouffe, E.
Auteure/Auteur
Lagrange, J.L.
Auteure/Auteur
Linassier, C.
Auteure/Auteur
Deplanque, G.
Auteure/Auteur
Beuzeboc, P.
Auteure/Auteur
Davin, J.L.
Auteure/Auteur
Martin, A.L.
Auteure/Auteur
Brihoum, M.
Auteure/Auteur
Culine, S.
Auteure/Auteur
Teuff, G.L.
Auteure/Auteur
Fizazi, K.
Auteure/Auteur
Liens vers les unités
ISSN
1938-0682
Statut éditorial
Publié
Date de publication
2023-10
Volume
21
Numéro
5
Première page
615.e1
Dernière page/numéro d’article
615.e8
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Randomized Controlled Trial ; Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases is not fully established.
Ancillary analysis from the GETUG 12 phase 3 trial. Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography (CT) scan were randomly assigned to receive androgen deprivation therapy (ADT) and docetaxel plus estramustine or ADT alone. Relapse-free survival (RFS), clinical RFS, metastases-free survival (MFS), overall survival (OS), and prostate cancer-specific survival (PCSS) were estimated using the Kaplan-Meier method for different levels of PSA (50 ng/mL, 75 ng/mL, and 100 ng/mL). The relationship between PSA and outcomes was studied using residual-based approaches and spline functions.
The median follow-up was 12 years (range: 0-15.3). Baseline PSA (<50 ng/mL, n = 328; ≥50ng/mL, n = 85) was associated with improved RFS (P = .0005), cRFS (P = .0024), and MFS (P = .0068). The 12-year RFS rate was 46.33% (CI 40.59-51.86), 33.59% (CI 22.55-44.97), and 11.76% (1.96-31.20) in men with PSA values <50 ng/mL (n = 328), 50-100 ng/mL (n = 68), and ≥100 ng/mL (n = 17), respectively. Exploratory analyses revealed no deviation from the linear relationship assumption between PSA and the log hazard of events.
Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.
Ancillary analysis from the GETUG 12 phase 3 trial. Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography (CT) scan were randomly assigned to receive androgen deprivation therapy (ADT) and docetaxel plus estramustine or ADT alone. Relapse-free survival (RFS), clinical RFS, metastases-free survival (MFS), overall survival (OS), and prostate cancer-specific survival (PCSS) were estimated using the Kaplan-Meier method for different levels of PSA (50 ng/mL, 75 ng/mL, and 100 ng/mL). The relationship between PSA and outcomes was studied using residual-based approaches and spline functions.
The median follow-up was 12 years (range: 0-15.3). Baseline PSA (<50 ng/mL, n = 328; ≥50ng/mL, n = 85) was associated with improved RFS (P = .0005), cRFS (P = .0024), and MFS (P = .0068). The 12-year RFS rate was 46.33% (CI 40.59-51.86), 33.59% (CI 22.55-44.97), and 11.76% (1.96-31.20) in men with PSA values <50 ng/mL (n = 328), 50-100 ng/mL (n = 68), and ≥100 ng/mL (n = 17), respectively. Exploratory analyses revealed no deviation from the linear relationship assumption between PSA and the log hazard of events.
Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.
PID Serval
serval:BIB_2588BC824A41
PMID
Open Access
Oui
Date de création
2023-06-07T11:07:09.365Z
Date de création dans IRIS
2025-05-20T18:40:55Z